Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1983 1
1992 2
1993 1
1995 1
1997 1
1998 1
2000 1
2001 3
2002 1
2007 1
2013 2
2014 3
2016 1
2017 2
2019 1
2020 1
2021 1
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Yasuda S, et al. N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2. N Engl J Med. 2019. PMID: 31475793 Clinical Trial.
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Free PMC article. Clinical Trial.
V2 receptor-mediated vasodilation in healthy humans.
Tagawa T, Imaizumi T, Shiramoto M, Endo T, Hironaga K, Takeshita A. Tagawa T, et al. Among authors: hironaga k. J Cardiovasc Pharmacol. 1995 Mar;25(3):387-92. doi: 10.1097/00005344-199503000-00006. J Cardiovasc Pharmacol. 1995. PMID: 7769802 Clinical Trial.
Association of Serum Oxysterols with Cholesterol Metabolism Markers and Clinical Factors in Patients with Coronary Artery Disease: A Covariance Structure Analysis.
Akiyama Y, Katsuki S, Matoba T, Nakano Y, Takase S, Nakashiro S, Yamamoto M, Mukai Y, Inoue S, Oi K, Higo T, Takemoto M, Suematsu N, Eshima K, Miyata K, Usui M, Sadamatsu K, Kadokami T, Hironaga K, Ichi I, Todaka K, Kishimoto J, Tsutsui H. Akiyama Y, et al. Among authors: hironaga k. Nutrients. 2023 Jun 30;15(13):2997. doi: 10.3390/nu15132997. Nutrients. 2023. PMID: 37447327 Free PMC article.
Association between Serum Oxysterols and Coronary Plaque Regression during Lipid-Lowering Therapy with Statin and Ezetimibe: Insights from the CuVIC Trial.
Nakano Y, Yamamoto M, Matoba T, Katsuki S, Nakashiro S, Takase S, Akiyama Y, Nagata T, Mukai Y, Inoue S, Oi K, Higo T, Takemoto M, Suematsu N, Eshima K, Miyata K, Usui M, Sadamatsu K, Kadokami T, Hironaga K, Ichi I, Todaka K, Kishimoto J, Tsutsui H. Nakano Y, et al. Among authors: hironaga k. J Atheroscler Thromb. 2023 Aug 1;30(8):907-918. doi: 10.5551/jat.63507. Epub 2022 Dec 1. J Atheroscler Thromb. 2023. PMID: 36450458 Free PMC article. Clinical Trial.
Temporal Trends in Antithrombotic Therapy for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention From 2014 to 2022 in Japan.
Nakano Y, Matoba T, Yamamoto M, Katsuki S, Koga Y, Mukai Y, Inoue S, Suematsu N, Higo T, Takemoto M, Miyata K, Usui M, Kadokami T, Tashiro H, Morishige K, Hironaga K, Tsutsui H; QcVIC Investigators. Nakano Y, et al. Among authors: hironaga k. Circ Rep. 2023 Jun 6;5(7):282-288. doi: 10.1253/circrep.CR-23-0047. eCollection 2023 Jul 10. Circ Rep. 2023. PMID: 37435100 Free PMC article.
Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial.
Takase S, Matoba T, Nakashiro S, Mukai Y, Inoue S, Oi K, Higo T, Katsuki S, Takemoto M, Suematsu N, Eshima K, Miyata K, Yamamoto M, Usui M, Sadamatsu K, Satoh S, Kadokami T, Hironaga K, Ichi I, Todaka K, Kishimoto J, Egashira K, Sunagawa K. Takase S, et al. Among authors: hironaga k. Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):350-358. doi: 10.1161/ATVBAHA.116.308388. Epub 2016 Dec 8. Arterioscler Thromb Vasc Biol. 2017. PMID: 27932353 Clinical Trial.
27 results